Mother turns cancer experience into children's book
Priyanka Pandya-Bhatt, from Aylesbury, Buckinghamshire, penned When Mummy Had Cancer as "a tool, to have open conversations and help families".
She said she was inspired by her daughters Keya, seven, and Shriyana, five, during those "two very difficult years" of treatment.
"My main focus was ensuring that the girls knew what was going on because I don't want them making up their own stories," she said.
The 39-year-old was diagnosed with triple negative breast cancer at the age of 36 and began writing the book while she underwent rounds of chemotherapy.
Mrs Pandya-Bhatt said she first discovered a lump in her breast at Easter 2022, which led to a mastectomy, chemotherapy, radiotherapy and reconstructive surgery.
By October 2023, she was "given the all clear" and was now in remission.
She said there had been plenty of advice for her and her husband Manoj Bhatt, but she felt her children were missing out.
"I thought, how much do you tell them, or don't tell them?" she said.
"I think the questions that I've incorporated into this book would help any family in any situation.
"Children should know they're not alone."
Lorna Russell, from Hope, a charity that supports young people aged five to 25 when a family member is diagnosed with a life-threatening illness, said "talking to children openly and honestly is really important as they can pick up on things really quickly".
"Whilst it's a conversation no parent wants to have, sitting down and letting the child know what's going on, and allowing them to ask questions about anything they don't understand, can help them feel like they have a bit more control in what is a really difficult situation for everyone," she said.
She said the charity had wellbeing advisers who young people could talk to and it was important "to remind children it's OK to still do the things they enjoy, and to have fun".
Mrs Pandya-Bhatt said her daughters were now "a lot more confident" and they "saw themselves reflected in the book".
"It's brought something very positive out of two very difficult years that were horrific," she said.
It has also led to her becoming a children's life coach.
She said that cancer was not always openly talked about in South Asian culture but "the community needs to come away from that".
"I'd rather speak to my children and tell them everything that I know, which has come from a professional, from someone with a medical background, rather than them Googling or going to a smart speaker."
Follow Beds, Herts and Bucks news on BBC Sounds, Facebook, Instagram and X.
'People are blamed if they have cancer'
How do I tell my four-year-old I have cancer?
Children's grief book about 'hope' not 'darkness'
Author in me
Hope
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 days ago
- Medscape
Other GU Cancers Share Germline Mutation Rates Seen in Ovarian Cancer
This transcript has been edited for clarity. Hello. I'm Dr Maurie Markman, from City of Hope. I'd like to discuss a very interesting and controversial topic. The paper I'm discussing is 'Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite Single-Institution Prospective Study,' published in the Journal of Urology . It has been well recognized for over a decade that patients with ovarian cancer need to have germline testing, independent of whether they have a family history of that particular cancer because we identified particular mutations — BRCA mutations, BRCA1 and BRCA2 — that may not be evident in the family by history but are very relevantpotentially for cascade testing of their family members later. Also, of course, in that setting, there are therapeutic implications for the use of PARP inhibitors. Increasingly, the discussion is about more universal testing for patients with breast cancer because of the incidences of BRCA and other mutations that are both relevant for treatment and for the question of genetic counseling for other members of the family. What about other tumor types? What about genitourinary (GU) cancers, as identified here? Should one take patients with all different kinds of GU tumors — prostate cancer, bladder cancer, kidney cancers, typically — and say there's a role for universal germline testing when a patient has been identified as having one of these cancers? To address this question, the group at the Mayo Clinic undertook comprehensive germline testing, examining for pathogenic germline variants at several sites from April 2018 to March 2020. This was a greater than 80-gene panel that was offered to patients. Today, that testing may be really quite different, but at that point it was greater than 80 genes that were tested for potential abnormality. A total of 601 patients enrolled with GU cancers. Again, this was across the sites and with GU cancers, regardless of a family history. There were 358 patients with prostate cancer, 106 with bladder cancer, and 137 with kidney cancer. Surprisingly, a majority of these patients, 86%, were male. Here is the important bottom line. Pathogenic germline variants, most with risk of high penetrance, were identified in 82 individuals, or 14% of the population. First, they were seen in almost the same percentage in kidney, bladder, and prostate cancer, and that 14% is not that far off. In fact, it's quite similar to the statement about ovarian cancer in terms of the overall population — 14% of the patients with GU cancer. Importantly, at this time, based on these data, fully 67% (or 2 of 3) patients had abnormalities that were potentially actionable. "Actionable" could mean a variety of things. It could mean there may be a therapy involved. It could mean that we need to talk to members of the family. They were not like, 'Oh, that's interesting, but there's nothing we can do about it.' For 2 out of 3, they could actually do something actionable. Importantly, of those 82 patients, 35% had at least one relative undergo cascade testing to examine for that variant. The bottom line here is that more than 1 of 8 patients in this unselected group of patients with GU cancers had a variant finding that was potentially pathogenic at the germline level. This would argue for — although there is going to be controversy and we need more data — universal testing, certainly of GU tumors, and one might ask for other tumor types. We need more data to confirm that. This would obviously be an extensive, new universal recommendation with costs associated with it, but this paper certainly raises that question that needs to be further examined. Thank you for your attention.
Yahoo
4 days ago
- Yahoo
New Data Analyses from Groundbreaking Pivotal Bridge to HOPE Clinical Trial Demonstrate Statistically Significant Clinical, Economic and Immunomodulatory Advantages in Liver Transplantation
Presentations showcased at World Transplant Congress in San Francisco demonstrate HOPE reduces the cost of liver transplantation by shortening the index hospitalization and decreasing late complications HOPE was associated with significantly less severe organ rejection and a significantly lower risk of steroid resistant organ rejection CHICAGO, Aug. 6, 2025 /PRNewswire/ -- Following the unveiling of 12-month follow-up results from the pivotal Bridge to HOPE trial during the World Transplant Congress (WTC) 2025 Plenary Session, additional analyses of the data demonstrate that Hypothermic Oxygenated Perfusion (HOPE), in conjunction with the VitaSmartTM Perfusion System, can provide significant cost-savings for hospital systems without compromising quality of care, and reduce the severity of organ rejection, including steroid resistant rejection. The results of these analyses were presented in oral abstract sessions by David Axelrod, MD, University Hospitals Cleveland Medical Center, OH ("Economic Assessment of Hypothermic Oxygenated Machine Perfusion in Liver Transplantation") and David J. Reich, MD, FACS, Drexel University, Philadelphia, PA ("Decreased Rejection Severity with Hypothermic Oxygenated Perfusion: Sub Analysis from a Pivotal Multicenter Trial of HOPE for Liver Transplantation"). The data were part of the 12-month follow-up study of the Bridge to Life Ltd. Bridge to Hope clinical trial (HOPE with VitaSmartTM Machine Perfusion System). "Building on the 12‑month follow‑up Bridge to HOPE clinical trial data presented in the Plenary Session, these additional analyses further strengthen the evidence for the value that HOPE used with the VitaSmart™ Perfusion System brings to the transplant community," said Don Webber, CEO and President of Bridge to Life Ltd., sponsor of the Bridge to HOPE clinical trial. "Bridge to Life is committed to partnering with Transplant Centers, Organ Procurement Organizations, and Hospitals to lower total cost of care while delivering the highest‑quality patient outcomes—by shortening hospital stays and reducing post‑transplant complications, including the risk of severe and steroid‑resistant rejection. Our broad presence at WTC 2025 underscores our leadership in advancing transplant science." In the economic analysis, compared with standard static cold storage (SCS), liver transplantation using HOPE reduced initial post-liver transplantation hospital length of stay (10.8 vs. 12.9 days), costs associated with biliary complications (20.2% vs. 24.6%), re-transplants (1.8% vs. 4.5%), and death (2.8% vs. 3.6%). Further, HOPE reduced one-year post-transplant costs by an average of $28,565, according to Centers for Medicare & Medicaid Services (CMS) data. Researchers concluded that HOPE for a minimum 1.5 hours at the recipient hospital reduced the cost of liver transplantation by shortening the index hospitalization and decreasing late complications. Additional financial benefits may include increased organ utilization, reduced staff overtime, and fewer high Model for End-Stage Liver Disease (MELD) transplants. In the review of the organ rejection data, moderate/severe biopsy-proven organ rejection was less common in HOPE than SCS (32% v 67%, p=.033). Ten patients developed steroid resistant organ rejection: one in the HOPE cohort and nine in the SCS group (4% v 43%, p=.003). Researchers concluded that while the prevalence of organ rejection was similar in HOPE and SCS, HOPE was associated with significantly less severe organ rejection and a significantly lower risk of steroid resistant organ rejection. These results highlight the immunomodulatory benefits of HOPE and warrant further research. About Bridge to Life™ LtdBridge to Life™ Ltd is a market leader in organ preservation solutions, offering premier products such as Belzer UW®, EasiSlush® and the VitaSmart™1 Hypothermic Oxygenated Perfusion System. With a strong focus on product quality, innovation and accessibility, the company serves and partners with leading Transplant Centers and Organ Procurement Organizations globally. 1VitaSmart™ is CE Marked and available for sale in several markets outside of the United States. VitaSmart™ is pending FDA approval in the United States. View original content to download multimedia: SOURCE Bridge to Life, Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
6 days ago
- New York Post
I've traveled the world to study brain health — here are 2 secrets to protecting against dementia
I'm going the extra mile for myelin. I travel the world to deliver neurological care in places with limited resources. Along the way, I have learned several important lessons about protecting brain health and preventing brain disease. My perspective was forever altered on one of my first trips to Uganda for the Department of Neurology at NYU Grossman School of Medicine. Advertisement I met a 14-year-old boy unable to move the left side of his body. Our medical team discovered the teen had undiagnosed and undetected HIV since birth. I was surprised to learn that HIV could be associated with stroke because it is an advanced feature of the virus that is infrequent in the US now. That knowledge changed my perceptions and attitudes towards brain health. Here is some wisdom from my visits to Uganda and Ghana, including two simple steps to halt and reverse brain damage. US vs the world The biggest difference in brain health challenges in the US and places like Ghana is simply access to care. Advertisement 3 Dr. Jaydeep Bhatt, director of the Division of Global Health for the Department of Neurology at NYU Grossman School of Medicine, reveals two major lessons for preventing brain disease. Most Americans can see their primary care physician to screen for risk factors leading to brain disease. Most Ghanaians do not have this level of access, so they are silently living with many risk factors. That leads to brain disease manifesting as a stroke or some other preventable brain disorder. A major, under-the-radar risk factor One risk factor for dementia that doesn't get a lot of attention is undetected hearing loss. Hearing loss is common with age. The problem is that good hearing is crucial for feeding the language centers, primarily located in the left hemisphere of the brain, with the proper information to produce language. Advertisement If hearing loss is not detected in a timely fashion, there might be improper funneling of information to this language area, increasing the risk of memory loss and dementia. Screening timetables Patients should be screened for brain-related conditions such as cognitive decline and stroke risk at least once a year. A preventative primary care physician will measure blood pressure, heart rate and cholesterol levels. Cardiovascular brain damage is tricky because it often has no immediate warning signs. High blood pressure is known in medicine as a 'silent killer' because you don't feel it as you're walking around. Advertisement 3 Bhatt visited Ghana and Uganda to study brain health. High blood pressure causes arteries and veins to narrow, which decreases nourishment and blood flow to the brain. This leads to changes detectable by modern MRI. Thankfully, these changes are in silent regions of the brain, so you will not have a disability. However, over time, memory loss, dementia and other harmful brain diseases can develop. High cholesterol, along with high blood pressure, contributes to these very same changes because it leads to blockages in important arteries that feed your brain with blood. Physical inactivity fuels high blood pressure, high cholesterol and other cardiovascular risk factors. Fortunately, brain damage from poor cardiovascular health can be stalled and even reversed. The traditional risk factors of high cholesterol, high blood pressure, diabetes and smoking are addressed by two behaviors — diet and exercise. Two ways to protect brain health When I traveled to Uganda and Ghana, one aspect of their diet that surprised me was their natural portion control. Advertisement The average Ghanaian and Ugandan meal is half or one-third the size of what we would expect of a meal in the US. American restaurants offer huge portions based on the idea that bigger is better, especially because it's more value for your money. But these larger meal sizes are just not meant for one person. So much of brain health is linked to the quality of your diet, including the amount you consume in one sitting. 3 The traditional risk factors of high cholesterol, high blood pressure, diabetes and smoking are addressed by two behaviors — diet and exercise. Advertisement Smaller portions and a lack of snacking between meals are inherent to cultures in Uganda and Ghana. Just by making more modest food choices at home, you can lessen your risk of brain disease. The right type of diet is not specific to one culture. Dietary approaches to stop hypertension or Mediterranean diets are rich in fruits and whole grains with low salt and less saturated fat. Exercise, which can occur in many different forms, is also essential to brain health. Advertisement No matter what neurological disease you may have heard of, the rate and severity of that disease are lessened with regular exercise. Exercise crosses cultures — I've seen it manifested in different ways as I've traveled the world and delivered neurological care. The other aspect of the culture in Uganda and Ghana that really struck me — in a good way — was the lack of alcohol and cigarette use. Drinking less alcohol and smoking less are well-established behaviors that lead to better brain health. The vast majority of both populations do not regularly partake in these activities. Advertisement Follow these recommendations to protect your brain as you age — and consult your physician with any concerns. Dr. Jaydeep Bhatt is the director of the Division of Global Health for the Department of Neurology at NYU Grossman School of Medicine.
